Mood, Anxiety, and Cognition in Perimenopause
The perimenopausal mood and cognitive picture is real and is one of the most commonly dismissed parts of the transition. Here is what current evidence supports — and how to think about HRT, SSRIs, therapy, and the conditions that need to be screened for separately.
This article is educational and is not medical advice. Consult your clinician before starting, stopping, or changing hormone therapy. Individual responses to HRT vary; the right hormones, doses, and delivery methods for you depend on your medical history and clinical context.
What is happening
The perimenopausal transition is associated with a measurable increase in the risk of new-onset depressive symptoms, particularly in women with a prior history of premenstrual mood symptoms, postpartum depression, or major depressive disorder. Anxiety often presents as a late-luteal-phase pattern that gradually loses its cyclical character as cycles become irregular. The cognitive complaints most commonly described — word-finding difficulty, losing the thread of a sentence, “brain fog” — appear in the perimenopausal years and, for most women, attenuate after the transition is complete.
HRT and mood: what is supported, what is not
Current menopause-society guidance supports a role for estradiol in the treatment of perimenopausal depressive symptoms in some patients, particularly those without a major depressive disorder history whose mood symptoms appeared with the transition itself. HRT is not a first-line treatment for major depressive disorder, and a woman whose depressive symptoms meet the criteria for a major depressive episode should be evaluated for treatment on that basis whether or not she is also a candidate for HRT.
Non-hormonal options
SSRIs and SNRIs have a substantial evidence base for both perimenopausal mood symptoms and vasomotor symptoms; some patients get meaningful improvement in both with one medication. Cognitive behavioural therapy is effective for depression, anxiety, and insomnia and is worth considering alongside or instead of medication. See non-hormonal options for the broader picture.
What needs to be screened for separately
- Thyroid dysfunction — overlaps substantially with perimenopausal mood and cognitive complaints.
- Sleep apnea — under-diagnosed in midlife women and a meaningful driver of low mood and cognitive symptoms.
- Substance use — alcohol intake often rises during the transition and is a meaningful driver of low mood and disrupted sleep.
- Major depressive disorder — needs its own treatment plan, with or without HRT.
Where to start
A clinician comfortable with both hormonal and non-hormonal approaches is the right starting point — most of the comprehensive practices we cover have this scope, and Evernow specifically includes non-hormonal options in its standard formulary. See the provider comparison.
If you are in crisis, please call or text 988 (the U.S. Suicide and Crisis Lifeline) or seek emergency care. This page is educational and is not a substitute for clinical evaluation.